Recombinant Rat ADCY8 Protein
Cat.No. : | ADCY8-519R |
Product Overview : | Recombinant Rat ADCY8 full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
Source : | Mammalian Cells |
Species : | Rat |
Tag : | His |
Form : | Liquid or lyophilized powder |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method. |
Purity : | >80% |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC. |
Storage Buffer : | PBS buffer |
Gene Name : | Adcy8 adenylate cyclase 8 (brain) [ Rattus norvegicus ] |
Official Symbol : | ADCY8 |
Gene ID : | 29241 |
mRNA Refseq : | NM_017142.1 |
Protein Refseq : | NP_058838.1 |
MIM : | |
UniProt ID : | P40146 |
Products Types
◆ Recombinant Protein | ||
ADCY8-337M | Recombinant Mouse ADCY8 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADCY8-2431H | Recombinant Human ADCY8 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADCY8-175R | Recombinant Rat ADCY8 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADCY8-1346M | Recombinant Mouse ADCY8 Protein | +Inquiry |
ADCY8-3182H | Recombinant Human ADCY8, His-tagged | +Inquiry |
◆ Lysates | ||
ADCY8-9020HCL | Recombinant Human ADCY8 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (14)
Ask a questionYes, targeting ADCY8 protein may have therapeutic potential in other diseases. For example, modulating ADCY8 activity may be beneficial in the treatment of neurological disorders such as Parkinson's disease and schizophrenia, as well as in obesity and certain cancers.
There are currently no drugs available that specifically target ADCY8 protein. However, drugs that affect the cAMP-PKA signaling pathway, such as glucagon-like peptide-1 (GLP-1) agonists used in the treatment of type 2 diabetes, indirectly affect ADCY8 activity.
Yes, targeting ADCY8 protein may be a potential therapeutic strategy for diabetes. Modulating ADCY8 activity can regulate insulin secretion and improve glucose homeostasis. However, further research is needed to determine the safety and efficacy of modulating ADCY8 in humans.
Developing drugs that specifically target ADCY8 protein can be challenging due to its complex regulation and interaction with other signaling pathways. Additionally, targeting ADCY8 may affect other physiological processes that could lead to unwanted side effects. Further research is needed to fully understand ADCY8's role in various diseases and to develop safe and effective therapeutics.
The potential side effects of targeting ADCY8 protein are not well known as this is an emerging area of research. However, as with any drug targeting a specific protein, potential side effects could include off-target effects, changes in related signaling pathways, and potential toxicity.
ADCY8 is being explored as a potential target in obesity treatment due to its role in regulating energy metabolism and appetite control. Modulating ADCY8 activity may help to improve energy expenditure and reduce food intake, leading to weight loss.
Measuring ADCY8 protein levels alone may not be sufficient for diagnosis of diseases. However, measuring ADCY8 activity or levels in conjunction with other diagnostic tests may provide additional information for disease diagnosis, prognosis, and treatment.
ADCY8 is being studied as a potential therapeutic target in neurological disorders, such as Parkinson's disease and schizophrenia, due to its role in neurotransmitter signaling and neuronal function. Modulating ADCY8 activity may help to improve synaptic plasticity and reduce cognitive impairment in these disorders.
There are currently no drugs that specifically target ADCY8 protein. However, compounds that modulate ADCY8 activity are being developed and tested for their therapeutic potential.
ADCY8 protein is regulated by a variety of factors, including hormonal and neural signals. For example, glucagon-like peptide-1 (GLP-1) and glucose signal through G protein-coupled receptors to activate ADCY8 and stimulate insulin secretion. Other factors, such as dopamine and calcium ions, can also modulate ADCY8 activity.
It is currently not possible to supplement ADCY8 protein for therapeutic purposes. However, the development of ADCY8 agonists or inhibitors may help to modulate ADCY8 activity for therapeutic benefit.
ADCY8 protein is not typically used as a direct diagnostic tool. However, measuring ADCY8 expression levels or genetic variants associated with ADCY8 may be useful in predicting disease outcomes and identifying patients who may benefit from certain treatments.
Yes, several genetic variants in the ADCY8 gene have been associated with various diseases and traits, including obesity, diabetes, and schizophrenia. These variants can affect ADCY8 expression levels, activity, and function, leading to altered signaling pathways.
ADCY8 protein is being studied in various research settings, including preclinical studies in animal models and in vitro studies to understand its role in disease and potential therapeutic targets. Clinical trials may also be conducted in the future to test the efficacy and safety of drugs targeting ADCY8 in humans.
Ask a Question for All ADCY8 Products
Required fields are marked with *
My Review for All ADCY8 Products
Required fields are marked with *
Inquiry Basket